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Abstract
Background: Persons with human immunodeficiency virus (HIV) have higher risks for myocardial infarction (MI)
than the general population. This is driven in part by higher type 2 MI (T2MI, due to coronary supply-demand
mismatch) rates among persons with HIV (PWH). In the general population, T2MI has higher mortality than type 1
MI (T1MI, spontaneous and generally due to plaque rupture and thrombosis). PWH have a greater burden of
comorbidities and may therefore have an even greater excess risk for complication and death in the setting of
T2MI. However, mortality patterns after T1MI and T2MI in HIV are unknown.
Methods: We analyzed mortality after MI among PWH enrolled in the multicenter, US-based Centers for AIDS
Research Network of Integrated Clinical Systems (CNICS) cohort (N = 28,186). Incident MIs occurring between
January 1, 1996, and December 31, 2014, were centrally adjudicated and classified as T1MI or T2MI. We first
compared mortality following T1MI vs. T2MI among PWH. Cox survival analyses and Bayesian model averaging
were then used to evaluate pre-MI covariates associated with mortality following T1MI and T2MI.
Results: Among the 596 out of 28,186 PWH who experienced MI (2.1%; 293 T1MI and 303 T2MI), mortality rates
were significantly greater after T2MI (22.2/100 person-years; 1-, 3-, and 5-year mortality 39%, 52%, and 62%) than
T1MI (8.2/100 person-years; 1-, 3-, and 5-year mortality 15%, 22%, and 30%). Significant mortality predictors after
T1MI were higher HIV viral load, renal dysfunction, and older age. Significant predictors of mortality after T2MI were
low body-mass index (BMI) and detectable HIV viral load.
Conclusions: Mortality is high following MI for PWH and substantially greater after T2MI than T1MI. Predictors of
death after MI differed by type of MI, reinforcing the different clinical scenarios associated with each MI type and
the importance of considering MI types separately.
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Background
The global prevalence of human immunodeficiency virus
(HIV) and burden of cardiovascular diseases among per-
sons with HIV (PWH) are increasing [1, 2]. Compared
with uninfected persons, PWH have greater risks for
myocardial infarction (MI) [3–6]. Although several stud-
ies have evaluated HIV-related factors and traditional
cardiovascular risk factors that contribute to elevated MI
risks among PWH [3, 6–10], little is known regarding
how these factors may contribute to prognosis after MI
in HIV.
Further complicating matters is the difference in MI
presentation in HIV versus in the general population.
Type 2 MIs (T2MIs), which are secondary to myocardial
supply/demand mismatch rather than primary plaque
rupture or thrombosis [11], account for as many as half
of HIV-associated MIs [9] but a lower [12] (though in-
creasing [13]) proportion of MIs in the general popula-
tion. Ascertainment, prevention, and treatment of MIs
in the general population have traditionally focused on
“classic” athero-thrombotic type 1 MIs (T1MIs) in part
because the clear majority of MIs in the general popula-
tion are T1MIs [14–20]. Comparatively sparse data exist
regarding prognosis, treatment, and prevention of
T2MIs, prompting investigators call for better under-
stand the biological basis and effective management
strategies of T2MI [13]. A recent single-center retro-
spective study in the general population found that 1-
year mortality after T1MI was 12.4% vs. 34.9% for T2MI
[21]. This difference was driven in large part by non-car-
diovascular causes of death following T2MI. Although
T2MI may be a particularly important prognostic
marker among PWH, who tend to have a greater chronic
disease burden, prognosis after T1MI and T2MI has not
been studied among PWH.
Given the need to better understand how the predic-
tors, course, and prognosis of MI subtypes differ among
PWH, we developed a unique and rigorous MI adjudica-
tion protocol in the Centers for AIDS Research Network
of Integrated Clinical Systems that distinguishes between
MI subtypes [22]. In these data, we found substantial
demographic and clinical differences between PWH with
incident T1MI vs. T2MI [12]. However, these analyses
did not extend to course after MI. Recent observational
studies have evaluated myocardial scar burden [23] and
mortality [24, 25] following MI in the population with
HIV but these studies did not distinguish MI subtype.
Therefore, the purpose of this analysis was to compare
mortality following T1MI vs. T2MI among PWH as well
as differences in clinical and demographic characteristics
associated with mortality by MI type. We hypothesized
that mortality would be significantly greater following
T2MI compared with T1MI among PWH and that fac-
tors that predict mortality would differ between MI
subtypes. Specifically, we hypothesized that traditional
cardiovascular risk factors most closely predict death fol-
lowing T1MI, whereas poor HIV control most closely
predicts death following T2MI.
Methods
Cohort, eligibility, and covariate assessment
We used the Centers for AIDS Research Network of In-
tegrated Clinical Systems (CNICS) cohort for all ana-
lyses. CNICS includes PWH in clinical care at 8 centers
for HIV care across the USA. We included data from the
6 CNICS sites (Johns Hopkins University, University of
Alabama at Birmingham, University of California-San
Diego, University of California-San Francisco, University
of North Carolina-Chapel Hill, and University of Wash-
ington) that completed adjudication of all detected inci-
dent MIs occurring between January 1, 1996, and
December 31, 2014. Covariates in the analysis are drawn
from the clinical data from all inpatient and outpatient
encounters occurring for all HIV-infected persons at
CNICS sites. Data in the CNICS repository include
demographic data, HIV transmission risk factors, labora-
tory test results, such as HIV viral load, CD4+ T cell
count, blood chemistries, cholesterol levels, and cardiac
biomarkers; prescription medications, such as lipid-low-
ering therapies, antihypertensive medications, and anti-
retroviral medications; clinical diagnoses such as
diabetes, hypertension, and smoking; patient-reported
measures such as depression and alcohol use; and vital
status including death dates. Each CNICS site obtained
institutional review board approval for CNICS, and writ-
ten informed consent was obtained from all CNICS par-
ticipants. Demographic and clinical characteristics used
for analyses were derived from the most recent visit
prior to MI. There was no cap on the duration of time
between the most recent visit at which a covariate was
measured and MI with the exception of HIV viral load
and CD4 T cell count, which were required within 3
years prior to MI for inclusion in this analysis. Other-
wise, we carried forward the most recent pre-MI values
over whatever time frame was appropriate. The median
time between the pre-MI covariate values and MI was 2
months (mean 4months).
Myocardial infarction adjudication
Procedures for screening and adjudication of MIs have
been described in detail [12, 22]. Possible MIs were iden-
tified by a screen for clinical MI diagnoses, coronary
intervention documentation, or elevated cardiac bio-
marker levels. Each CNICS site also requested relevant
medical records for any of their participants with re-
ported or suspected MIs at outside hospitals. Sites then
assembled de-identified packets of clinical notes, rele-
vant cardiovascular and imaging studies, and laboratory
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tests which were reviewed independently by two expert
physician adjudicators. Antiretroviral medication names
were redacted to eliminate the potential for biasing re-
viewers based on perceived associations between specific
antiretroviral medications and MIs. Two expert cardiolo-
gist adjudicators independently reviewed these data to
determine whether CNICS participants had definite,
probable, or no MI, and subsequently categorized events
as T1MI or T2MI. Determination of MI presence and
subtype included electrocardiographic criteria of evolv-
ing Q waves, ST elevations, and new left bundle branch
block with specific algorithms used in the presence or
absence of chest pain and cardiac biomarker elevations
to determine whether MIs were definite, probable, or
not present. Reviewers categorized MIs as T1MI or
T2MI; definition of T2MI required identification of a
clinical cause leading to the T2MI, such as an MI occur-
ring during sepsis. A third expert cardiologist adjudica-
tor was used to resolve discrepancies. Type 3 MIs were
not included because these occur without available bio-
markers, and there were < 10 MIs in the cohort that
would have been categorized as type 4 or 5 MIs; thus,
only type 1 and 2 MIs were included. Coronary interven-
tions such as coronary artery bypass graft surgery were
combined with T1MI. Only the first MI was included for
analysis for CNICS participants with multiple MIs.
Mortality ascertainment
Deaths were ascertained for all CNICS participants at
the local, state, and national level using multiple ap-
proaches including state death certificate data and na-
tional death indexes.
Statistical analysis
Follow-up started at the date of the MI and ended at the
earliest of the date of death or date of censoring. The
date of censoring was 18months before the latest re-
corded death at each site in order to adequately ensure
capture of deaths, given potential delays in death index
data. All covariates were collected at least 7 days before
the MI date to preclude MI-related treatment or labora-
tory changes to covariates. Due to this covariate collec-
tion date requirement, only MIs at least 7 days after the
initial CNICS visit date were included. Regarding miss-
ing data, there were a total of 11 participants excluded
because they did not have complete HIV viral load and
CD4 T cell count data within 3 years prior to MI; the
only other variable with missing data was body-mass
index (BMI), which was 5.7% missing and for which
missing data were handled with multiple imputation.
We used 3 approaches to identify potential predictors
of death. First, Cox survival models were used to investi-
gate the association of MI with covariates that were
chosen a priori as clinically important. Second, to allow
for variable selection into a more parsimonious statis-
tical model and decide between potentially collinear pre-
dictors, Bayesian model averaging [26, 27] as applied to
Cox models [28] was used to select potentially important
covariates. We used a threshold of > 30% posterior prob-
ability of a predictor being included in the statistical
model based on the goodness of fit of the family of pos-
sible models. Once the predictors were selected using
Bayesian model averaging, Cox survival models with the
selected covariates with high posterior probabilities of
selection were used to estimate the associated hazard ra-
tios for T1MI and T2MI. This was our primary analysis,
as it allows a principled approach to selecting among
highly correlated covariates. We also performed sensitiv-
ity analyses in which we repeated these analyses exclud-
ing persons who died within 30 days after MI in order to
better isolate MI as an exposure rather than a near-con-
current outcome with death. Given the possibility that
sepsis would precipitate many T2MIs and would affect
post-MI mortality, we also performed a sensitivity ana-
lysis of mortality following T2MIs in which persons with
and without sepsis were analyzed separately.
Results
Of 28,186 PWH from across the USA eligible for ana-
lyses, 596 (2.1%) experienced MIs (293 T1MIs and 303
T2MIs: Table 1). Compared to people with T1MI, people
with T2MI were more likely to be female and African-
American; they were also more likely to use injection
drugs, less likely to take antiretroviral therapy, and had
lower CD4 counts and higher HIV viral loads prior to
MI than participants with T1MI (data not shown as we
have published these previously [12]). The most com-
mon cause of T2MI was sepsis or bacteremia, which
accounted for 35% of T2MI; the next most common
causes were cocaine or other illicit drug use (14% of
T2MI), followed by hypertensive urgency or emergency
(10%) and respiratory failure (9%) [12].
Mortality rates were significantly greater following
T2MI (22.2 deaths per 100 person-years; 54.1% overall)
than T1MI (8.2 deaths per 100 person-years; 36.2% over-
all) (Table 2). Participants with T2MI were particularly
likely to die early during follow-up; mortality at 1, 3, and
5 years after MI was 39%, 52%, and 62% for T2MI versus
15%, 22%, and 30% for T1MI (Fig. 1).
Among participants with T1MI, those who died during
follow-up were significantly older and had significantly
higher HIV viral loads, lower CD4 counts, and lower
body-mass index (BMI) prior to MI than participants
who did not die during follow-up (Table 2). Among par-
ticipants with T2MI, those who died during follow-up
had significantly higher HIV viral load, lower BMI, and
lower estimated glomerular filtration rate (eGFR) prior
to their MI compared with those who did not die during
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follow-up. On univariate analyses used for model selec-
tion, older age was associated with a significantly ele-
vated risk for death after T1MI but not after T2MI
(Table 3). Black race was associated with a borderline
higher risk for death after T1MI but not T2MI in uni-
variate analyses, but was no longer a significant pre-
dictor in multivariable analyses or when Bayesian model
averaging was used to select significant predictors of post-
MI mortality. Factors significantly associated with elevated
rates of death following T1MI were eGFR < 30mL/min/
1.73m2, older age, and higher viral load prior to MI (Table
3). Meanwhile, for T2MI, only BMI < 18.5 kg/m2 was as-
sociated with a significantly elevated hazard of death and
BMI 25–30 kg/m2 was associated with a significantly
lower hazard of death (Table 3).
When we used the Bayesian Model Averaging to deter-
mine factors most likely to predict mortality following
MI, several HIV-related factors were associated with
post-MI mortality. The predictors of elevated mortality
after T1MI were higher pre-MI log10 of HIV viral load,
eGFR < 30mL/min/1.73m2, and older age (Table 4), all
of which had a posterior probability of at least 95% of
being in the best fitting statistical model. The predictors
of greater mortality after T2MI were body mass index <
18.5 kg/m2 and HIV viral load > 400 copies/mL, with
posterior probabilities between 30 and 40%; body-mass
index 25.0 to 29.9 kg/m2 prior to T2MI was associated
with a significantly lower hazard of subsequent mortality
(Table 4) with a posterior probability greater than 95%.
In sensitivity analyses excluding participants who died
within 30 days of MI, eGFR < 30mL/min/1.73m2 and
older age were significant predictors of mortality following
T1MI (Additional file 1: Table S1). After T2MI, eGFR <
30mL/min/1.73m2 and BMI < 18.5 kg/m2 were associated
with significantly elevated mortality (Additional file 1:
Table S1). When we analyzed mortality after T2MI
separately for persons with and without sepsis, the mor-
tality rates were greater among those with sepsis, but
mortality for persons with T2MI without sepsis was still
substantially greater than mortality for persons with T1MI
(Fig. 2).
Discussion
We evaluated predictors of mortality following MI in a
large, multicenter HIV cohort with long-term follow-up
and rigorous MI adjudication. We found that mortality
is high for PWH after MI and, similar to the general
population, mortality is particularly high after T2MI. We
found that one-year mortality for PWH was 15% after
T1MI and 39% after T2MI—these were similar to a re-
cent report from the general population (12.4% and
34.9% 1-year mortality after T1MI and T2MI, respect-
ively) [21]. Nevertheless, our observed mortality rates
after T1MI for PWH were generally higher than those
observed after acute coronary syndromes or percutan-
eous coronary intervention for PWH in other, primarily
European, cohorts [25, 29–31]. While this is somewhat
expected because we analyzed mortality after MI only
and did not include people with non-MI acute coronary
syndromes (which are by definition less severe and asso-
ciated with less morbidity and mortality), differences in
clinical and behavioral risk factor burden, as well as clin-
ical management and access to care, between PWH in
the United States and Europe may also underlie the dif-
ferences in observed post-MI mortality rates. We found
that older age was associated with significantly greater
mortality risk following T1MI but not T2MI, whereas
for T2MI, low BMI was associated with a significantly
greater mortality risk. Renal dysfunction prior to MI was
associated with significantly elevated mortality regardless
of MI type.
Table 1 Demographics and clinical characteristics for persons
with HIV by mortality status following myocardial infarction
MI
Variable: N (%) or mean (SD)* Type 1 Type 2 P value
N 293 303
Age 51 (9) 49 (11) 0.02
Female (%) 49 (17) 82 (27) 0.002
Ethnicity < 0.001
White 149 (51) 73 (24)
Black 115 (39) 205 (68)
Hispanic 20 (7) 18 (6)
Other/missing 9 (3) 7 (2)
Log10(HIV viral load (VL) + 1) 2.4 (1.4) 3.1 (1.6) < 0.001
Log10(max VL + 1) 4.8 (1.1) 4.9 (1.1) 0.3
CD4 436 (304) 333 (292) < 0.001
Nadir CD4 174 (174) 168 (201) 0.7
BMI** < 0.001
< 18.5 13 (4) 31 (10)
18.5 to < 25 111 (38) 138 (46)
25 to < 30 100 (34) 64 (21)
≥ 30 60 (20) 45 (15)
Missing BMI 9 (3) 25 (8)
Diabetes 74 (25) 69 (23) 0.5
eGFR < 30 mL/min/1.73m2 33 (11) 51 (17) 0.05
Statin use 84 (29) 41 (14) < 0.001
Treated hypertension 98 (33) 93 (31) 0.5
Smoker 134 (46) 130 (43) 0.5
*Demographic and clinical characteristics are derived from the most recent
visit prior to MI
**9 people with type 1 MI were missing BMI measurements (7 of whom died
during follow-up) and 25 people with type 2 MI were missing BMI
measurements (19 of whom died during follow-up)
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Perhaps the most likely explanation for the finding
that older age was associated with mortality after T1MI
but not T2MI relates to the different underlying demo-
graphic and clinical factors associated with T1MI versus
T2MI. T1MIs generally result from atheromatous coron-
ary plaque development and overlying thrombosis; this
plaque burden reflects decades’ worth of exposure to
cardiovascular disease (CVD) risk factors (such as dia-
betes, hypertension, smoking, and dyslipidemia, among
others) that contribute fairly predictably to vascular
aging. Older PWH with T1MI may thus tend to be glo-
bally sicker than younger HIV-infected persons with
T1MI given their accumulated longitudinal exposure to
CVD risk factors and comorbidities, which are them-
selves associated predictably with morbidity and mortal-
ity. It may also suggest that younger age was less
protective against mortality in the T2MI population,
given that the mortality rate was higher among the
T2MIs than the T1MIs (Fig. 1). Even more striking, the
mean age was lower for fatal T2MIs than non-fatal
Table 2 Demographics and clinical characteristics for persons with HIV by mortality status following myocardial infarction
Type 1 MI Type 2 MI
Variable: N (%) or mean (SD)* Lived Died P value Lived Died P value
N 187 106 139 164
Age 50 (9) 52 (9) 0.05 50 (11) 48 (11) 0.1
Female (%) 32 (17) 17 (16) 0.8 35 (25) 47 (29) 0.5
Ethnicity 0.2 0.2
White 102 (55) 47 (44) 35 (25) 38 (23)
Black 65 (35) 50 (47) 90 (65) 115 (70)
Hispanic 15 (8) 5 (5) 12 (9) 6 (4)
Other/missing 5 (3) 4 (4) 2 (1) 5 (3)
Log10(HIV viral load (VL) + 1) 2.2 (1.4) 2.8 (1.5) 0.001 2.8 (1.6) 3.3 (1.6) 0.002
Log10(max VL + 1) 4.8 (1.1) 4.8 (1.2) 0.9 4.8 (1.1) 5.0 (1.1) 0.04
CD4 472 (313) 372 (276) 0.005 361 (291) 310 (291) 0.1
Nadir CD4 186 (184) 154 (154) 0.1 185 (224) 153 (179) 0.2
BMI** 0.005 0.002
< 18.5 5 (3) 8 (8) 8 (6) 23 (14)
18.5 to < 25 71 (38) 40 (38) 66 (47) 72 (44)
25 to < 30 63 (34) 37 (35) 39 (28) 25 (15)
≥ 30 46 (25) 14 (13) 20 (14) 25 (15)
Missing BMI 2 (1) 7 (7) 6 (4) 19 (12)
Diabetes 44 (24) 30 (28) 0.4 31 (22) 38 (23) 0.9
eGFR < 30 mL/min/1.73m2 15 (8) 18 (17) 0.02 15 (11) 36 (22) 0.01
Statin use 52 (28) 32 (30) 0.7 24 (17) 17 (10) 0.08
Treated hypertension 63 (34) 35 (33) 0.9 52 (37) 41 (25) 0.02
Smoker 93 (50) 41 (39) 0.07 61 (44) 69 (42) 0.8
*Demographic and clinical characteristics are derived from the most recent visit prior to MI
**9 people with type 1 MI were missing BMI measurements (7 of whom died during follow-up) and 25 people with type 2 MI were missing BMI measurements (19
of whom died during follow-up)
Fig. 1 Survival following type 1 and type 2 myocardial infarction
among HIV-infected patients
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T2MIs (Table 1), suggesting that a diagnosis of T2MI is
an indicator of more severe underlying comorbidity as-
sociated with mortality at younger ages.
Although patients with T2MI may have high cumula-
tive exposure to CVD risk factors, they are substantially
more likely to have severe non-cardiovascular comorbid-
ities that are not as clearly or predictably associated with
aging [19]. Thus, PWH with T2MI may be similarly
“sick” regardless of age, as their extent of comorbidity
may not be due to long-term accumulation of aging-
Table 3 Hazard ratios for mortality among persons with HIV following type 1 and type 2 myocardial infarction: univariate regression
Variable Hazard ratio for death (95% confidence interval) P value Hazard ratio for death (95% confidence interval) P value
Type 1 MI Type 2 MI
Antiretroviral use 0.62 (0.39–0.98) 0.04 0.74 (0.54–1.01) 0.06
Female sex 1.03 (0.61–1.73) 0.92 1.23 (0.88–1.73) 0.23
Age (per 10 years older) 1.54 (1.23–1.93) < 0.01 0.91 (0.79–1.05) 0.20
Ethnicity
Black 1.49 (1.01–2.18) 0.04 1.07 (0.76–1.49) 0.71
Hispanic 0.84 (0.34–2.08) 0.71 0.55 (0.24–1.24) 0.15
Other/missing 1.51 (0.55–4.11) 0.42 1.68 (0.69–4.10) 0.25
CD4 (per 100) 0.93 (0.86–1.00) 0.05 0.96 (0.90–1.01) 0.12
Log10(VL + 1) 1.16 (1.02–1.32) 0.02 1.11 (1.01–1.22) 0.03
Diabetes 1.49 (0.97–2.28) 0.07 1.03 (0.72–1.48) 0.87
eGFR < 30 mL/min/1.73m2 2.51 (1.50–4.22) < 0.01 1.30 (0.90–1.89) 0.16
Treated hypertension 1.12 (0.74–1.68) 0.59 0.66 (0.46–0.94) 0.02
Smoker 0.76 (0.51–1.12) 0.17 0.97 (0.71–1.32) 0.83
BMI < 18.5 kg/m2 1.66 (0.82–3.35) 0.16 1.86 (1.21–2.88) < 0.01
BMI 25 to < 30 kg/m2 0.98 (0.65–1.46) 0.91 0.50 (0.33–0.77) < 0.01
BMI ≥ 30 kg/m2 0.61 (0.36–1.04) 0.07 1.11 (0.73–1.69) 0.61
Table 4 Significant predictors of mortality following type 1 and type 2 myocardial infarction among persons with HIV: Bayesian
Model Averaging
Variable Probability of inclusion
in the final model (%)
HR* 95% CI* P value Probability of inclusion
in the final model (%)
HR* 95% CI* P value
Type 1 MI
Statin use 3.3 4.5
ART use 8.8 11.5
Female 2.9 0.91 0.53, 1.55 0.723 6.7 1.24 0.88, 1.75 0.219
Diabetes 13.9 3.4
Treated hypertension 2.0 19.9




Log10(VL + 1) 95.1 1.25 1.09, 1.43 0.001 21.0
CD4 (per 100) 4.5 4.3
VL > 400 24.4 33.6 1.38 1.00, 1.91 0.047
eGFR < 30 100.0 3.02 1.77, 5.14 < 0.001 11.1
BMI < 18.5 9.1 37.9 1.62 1.02, 2.56 0.040
BMI 25 to < 30 1.9 96.7 0.55 0.35, 0.86 0.009
BMI 30+ 20.0 1.8 1.05 0.68, 1.64 0.819
*Hazard ratio and confidence interval from Cox model included for potential significant predictors plus age and sex
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associated exposures. The steep mortality slope apparent
for participants with T2MI due to sepsis (compared with
T1MI and, to a lesser extent, T2MI not due to sepsis)
suggests that a substantial portion of the post-MI mor-
tality among those with T2MI, particularly T2MI due to
sepsis, relates to the event (e.g., sepsis) associated with
the T2MI.
The differences we observed in predictors of mor-
tality following T1MI vs. T2MI reflect the diverse
pathophysiologies and concomitant comorbidities
associated with these different MI subtypes. The sub-
stantially greater mortality after T2MI versus after
T1MI for PWH raises the question of whether the
difference is driven by (1) critical illnesses (e.g.,
sepsis) leading to the T2MIs, (2) underlying patient
risk factors (e.g., intravenous drug use and poor HIV
control) that led to these critical illnesses, and/or (3)
cardiac damage incurred during the T2MIs. Unfortu-
nately, T2MI is a heterogeneous condition for which
optimal prevention and treatment are far less clear
than T1MIs, for which revascularization and pharma-
cologic strategies have dramatically altered the post-
event natural history. This heterogeneity in T2MI
triggers may be particularly notable among PWH
given the severity of HIV-associated critical systemic
illnesses, such as opportunistic infections and associ-
ated sepsis. The greater mortality rates following
T2MI that we observed among HIV-infected persons
with low BMI (compared with normal BMI) are not
surprising given the association of low BMI with mor-
tality in general, and likely reflect the known greater
burden of HIV-associated wasting, malnourishment,
and/or concomitant high-risk behaviors (e.g., intraven-
ous drug use) among underweight PWH [32–34].
Our findings should be interpreted in the context of
this study’s limitations. A key premise of this study is
that T1MI and T2MI are fundamentally different; there
is heterogeneity in the pathophysiology of T2MIs as
well as how they are defined and assessed [14, 35].
To ensure optimal validity in MI ascertainment, MIs
were adjudicated by two independent cardiologists
(and a third where disagreements occurred) using
rigorous and pre-specified criteria. Another limitation
of this study is the possibility that MIs occurring out-
side of CNICS sites were not ascertained. We sought
to address this potential limitation by asking sites to
request relevant medical records for any of their par-
ticipants with reported or suspected MIs at outside
hospitals. As with any observational study, we were
unable to infer causality between exposures at the
time of MI and subsequent mortality risk. Addition-
ally, because valid cause-specific mortality data are
not available in CNICS at this time, we were unable
to assess underlying causes of death in this analysis.
We were also unable to comprehensively define dif-
ferences in mortality between CNICS sites; such dif-
ferences are certainly possible given differences in
demographics and CVD risk factors across CNICS
sites. Nevertheless, the CNICS cohort represents a
fundamental strength of this analysis, as it is a large,
geographically and ethnically diverse cohort that has
prospectively collected comprehensive clinical data on
HIV-infected persons receiving clinical care for nearly
two decades. This underscores the generalizability of
our findings to PWH in clinical care more generally.
Finally, our approaches to variable selection allowed
us to decide between potentially quite collinear covar-
iates to build the model most consistent with the
underlying data.
Conclusions
We found that post-MI mortality rates for PWH are ele-
vated in general and particularly elevated after T2MI, in
a diverse, multi-center cohort of over 28,000 PWH with
rigorous MI adjudication. The relative difference we
found in mortality after T1MI and T2MI for PWH was
similar to that of uninfected persons. High HIV viral
load was associated with death after T1MI and T2MI,
underscoring the importance of HIV viral suppression
even in the setting of competing risks for non-AIDS
events such as MI. We also found that older age is asso-
ciated with greater mortality following T1MI, but not
T2MI, whereas low BMI is associated with greater mor-
tality following T2MI. These differences reflect the clin-
ical, demographic, and pathophysiological differences
between T1MI and T2MI and may be particularly rele-
vant given the high proportion of MIs in HIV that are
type 2. Further studies are needed to identify optimal ap-
proaches to preventing morbidity and mortality after MI
among PWH.
Fig. 2 Survival following type 1 myocardial infarction, type 2
myocardial infarction due to sepsis, and type 2 myocardial infarction
not due to sepsis among HIV-infected patients
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